TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24452168
Drug: PCR testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCR testing with concurrent antistaphylococcal antibiotics
Study: 22952075
Drug: Oral tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tropisetron at 5 mg/day
Study: 22952075
Drug: Oral tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tropisetron at 10 mg/day
Study: 22952075
Drug: Oral tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tropisetron at 20 mg/day
Study: 20937929
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (CEE plus medroxyprogesterone acetate 2.5 mg/d)
Study: 10805061
Drug: Flosequinan 50
Normalized name: flosequinan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 50 mg
Study: 10805061
Drug: Flosequinan 100
Normalized name: flosequinan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 100 mg
Study: 10805061
Drug: Flosequinan 150
Normalized name: Flosequinan
DrugBank: Flosequinan (DB13228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 150 mg
Study: 7685176
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril twice a day
Study: 27626622
Drug: Sertraline, 100
Normalized name: Sertraline, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, 100 mg/d for 24 weeks
Study: 20695007
Drug: 4.5mg nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5mg nightly naltrexone (low-dose naltrexone, LDN)
Study: 19029083
Drug: 0-50 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-50 ng/mL rhVEGF(165) for 7 days in vitro
Study: 19029083
Drug: 0 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 or 50 ng/mL rhVEGF(165) for one hour prior to implantation
Study: 16179956
Drug: NMR pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMR pulse sequences; treatment duration: 9 days
Study: 12706694
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (3 doses of 25 microg of protein each, with 6 weeks interval and a third dose after 10 months)
Study: 12706694
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination (4 weekly doses followed by a fifth dose after 5 months, each dose consisting of OMVs equivalent to 250 microg of protein)
Study: 8678499
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THP vesical irrigation
Study: 8678499
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg THP vesical irrigation
Study: 22681244
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing prophylaxis
Study: 22681244
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic dosing regimen
Study: 16186372
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection (IVI) of 4 mg triamcinolone acetonide (TA)
Study: 16186372
Drug: Sub-Tenon's infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's infusion (STi) of 40 mg triamcinolone acetonide (TA)
Study: 14578254
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IGT and NCEP definitions
Study: 14578254
Drug: NCEP definition
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCEP definition with fasting glucose >or=5.4 mmol/l
Study: 10947341
Drug: Zanamivir treatment
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir treatment (bid)
Study: 10947341
Drug: Zanamivir treatment
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir treatment (qid)
Study: 10947341
Drug: Zanamivir treatment
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir treatment (bid and qid)
Study: 8777296
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxycillin, and bismuth)
Study: 8777296
Drug: Loxiglumide (LOX)
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (LOX) administration after Hp eradication
Study: 1806610
Drug: Calcium (calcium
Normalized name: Slow-Mag with Calcium (calcium carbonate 298 MG (calcium 119 MG) / magnesium chloride 596 MG (magnesium 71.5 MG)) Delayed Release Oral Tablet, Reformulated Feb 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (calcium carbonate with meals to attain an intake of 1,700 mg daily)
Study: 6749443
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Study: 6749443
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Study: 31348579
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg at 2-week intervals
Study: 21863237
Drug: PX-12 administered
Normalized name: PX-12
DrugBank: PX-12 (DB05448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-12 administered at 400 mg/m(2)/day by 72-hour infusion
Study: 23561002
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen (IBUg)
Study: 21525198
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg riboflavin for 8 weeks
Study: 21525198
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg riboflavin for 8 weeks
Study: 9117838
Drug: Topical streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical streptokinase
Study: 8478851
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block using steroid/bupivacaine
Study: 24917198
Drug: Pregnenolone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (titrated to 500 mg/day)
Study: 22532639
Drug: Continuous NSAID
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous NSAID treatment
Study: 22532639
Drug: On-demand NSAID
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand NSAID treatment
Study: 22532639
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (continuous and on-demand)
Study: 20360277
Drug: Psychiatric advance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric advance directives (PADs) documenting medication preferences
Study: 20360277
Drug: Being prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Being prescribed at least one medication requested in the psychiatric advance directive
Study: 19670189
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) therapy
Study: 18585837
Drug: Calcineurin-inhibitor (CNI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin-inhibitor (CNI) therapy (Control)
Study: 12934178
Drug: Indinavir/ritonavir (Idv/Rtv;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (Idv/Rtv; 800/100 mg 2 times daily)
Study: 12934178
Drug: Saquinavir/ritonavir (Sqv/Rtv;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir (Sqv/Rtv; 1000/100 mg 2 times daily)
Study: 10800876
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol and 500 microg ipratropium
Study: 10800876
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol
Study: 24641586
Drug: Cholecalciferol 10,000
Normalized name: CHOLECALCIFEROL 10,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 10,000 IU weekly, titrated up to 50,000 IU weekly if necessary
Study: 22564753
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of fenofibrate per each hemodialysis day for 4 weeks
Study: 17671159
Drug: L‐BLP25 (peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐BLP25 (peptide vaccine)
Study: 9445297
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD)
Study: 2133623
Drug: 20 mmol
Normalized name: dibasic potassium phosphate 120 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mmol Mg‐aspartate‐HCl/d for 3 months
Study: 17080543
Drug: Both acupuncture
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both acupuncture and physical therapy
Study: 11557462
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 75 mg
Study: 11557462
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 150 mg
Study: 11557462
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 300 mg
Study: 11557462
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF 600 mg
Study: 7841749
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunosuppressive agents)
Study: 3074295
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet with standard antihypertensive therapy
Study: 3074295
Drug: Captopril administration
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril administration (25‐50 mg/day) for 4 weeks
Study: 31704275
Drug: Transcranial infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial infrared brain stimulation (TIBS), a form of photobiomodulation (PBM), details on dosage and duration not available.
Study: 31315657
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture (Ecologic® Barrier; 2.5 × 10^9 colony forming units/g; 2 g; daily)
Study: 29191799
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention website addressing barriers to organ donation through videos; no specific dosage or duration mentioned.
Study: 29191799
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention website; no specific dosage or duration mentioned.
Study: 21368061
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent motor execution (baseline)
Study: 16810002
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.05 mg . kg(‐1) . h(‐1), approximately 3 mg/h)
Study: 15502035
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of hyperbaric bupivacaine 0.5% (n = 20)
Study: 15502035
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of hyperbaric levobupivacaine 0.5% (n = 20)
Study: 15502035
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of hyperbaric ropivacaine 0.5% (n = 20)
Study: 11676331
Drug: Triple-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug regimen (lansoprazole, clarithromycin, secnidazole)
Study: 11676331
Drug: Quadruple-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple-drug regimen (lansoprazole, amoxycillin, colloidal bismuth subcitrate, secnidazole)
Study: 9634207
Drug: Anti-retroviral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-retroviral treatment (Zidovudine)
Study: 19042322
Drug: Cognitive-behaviorally-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviorally-based treatment for AOSUD
Study: 12036665
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of latanoprost 0.005%/timolol maleate 0.5%
Study: 12036665
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of latanoprost 0.005%/timolol maleate 0.5%
Study: 12036665
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate given twice daily
Study: 12036665
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of latanoprost/timolol
Study: 7972188
Drug: Inpatient accommodation
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient accommodation for oncology patients receiving radiotherapy treatment
Study: 2689909
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose morphinic administered for induction and maintenance of anesthesia without further analgesic and/or narcotic supplement.
Study: 769772
Drug: L-dopa (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (up to 1250 mg daily)
Study: 30835911
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human soluble thrombomodulin (rhTM) at a dosage of 380 U/kg/day for 6 days
Study: 30835911
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control arm)
Study: 28817370
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo)
Study: 24041815
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii 50 mg/kg every 12 h
Study: 16753687
Drug: 1 IOVE
Normalized name: Ioversol
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 IOVE capsule per day (Group 1; n = 562)
Study: 16753687
Drug: 2 IOVE
Normalized name: Ioversol
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 IOVE capsules per day (Group 2; n = 518)
Study: 15484298
Drug: Oxymatrine capsule
Normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine capsule (group A)
Study: 11777288
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg orally daily)
Study: 11777288
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg intravenously four times daily)
Study: 30614286
Drug: Lidocaine plaster
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine plaster (700 mg)
Study: 24863037
Drug: 1.4% LSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% LSO gel
Study: 21078493
Drug: anti-dsDNA antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-dsDNA antibodies
Study: 21078493
Drug: antinucleosome antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: antinucleosome antibodies
Study: 21078493
Drug: anti-C1q antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-C1q antibodies
Study: 16941030
Drug: Celecoxib, 400
Normalized name: Celecoxib, 400 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 400 mg b.i.d.
Study: 16941030
Drug: Diclofenac, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac, 75 mg b.i.d.
Study: 16941030
Drug: Ibuprofen, 800
Normalized name: Ibuprofen, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 800 mg three times a day.
Study: 1489126
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (28 mg)
Study: 1489126
Drug: Inhaled torasemide
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled torasemide (28 mg)
Study: 30646197
Drug: Manual therapy/individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy/individualized exercise
Study: 24561636
Drug: 5-week neck
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-week neck strengthening intervention performed twice per week
Study: 10087420
Drug: Doxium (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxium (calcium dobesilate) 2 g daily until delivery
Study: 2333739
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.3 g protein/dl and 55:45 whey: casein ratio
Study: 2333739
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.4 g/dl protein; 55:45 whey: casein ratio
Study: 2333739
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.5 g/dl protein; 55:45 whey: casein ratio
Study: 2333739
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.4 g/dl protein; 60:40 whey: casein ratio
Study: 2333739
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.4 g/dl protein; 20:80 whey: casein ratio
Study: 2333739
Drug: All formulas
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All formulas containing 0.7 mg iron and 0.7 mg zinc/dl
Study: 453775
Drug: Prazosin (Pz)
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin (Pz) 2 mg t.i.d.
Study: 453775
Drug: Methyldopa (MD)
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa (MD) 250 mg t.i.d.
Study: 453775
Drug: Prazosin (Pz)
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin (Pz) + Diuretic
Study: 27640922
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose shockwave therapy
Study: 20471117
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment before PCI (control group)
Study: 17260161
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of hyperammonemia by administration of a solution mimicking the amino acid composition of haemoglobin (60)
Study: 14696754
Drug: 30 or
Normalized name: Oseni 25/30 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 or 60 mg folic acid with or without vitamins B6 and B12 for eight weeks
Study: 14696754
Drug: Intravenous folinic
Normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous folinic acid given alone or with serine for eight weeks
Study: 9191629
Drug: Educational materials
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational materials (medication booklet, behavioral health booklet, video)
Study: 28384657
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy (4-drug oral regimen: daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide)
Study: 28384657
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy (4-drug oral regimen)
Study: 19556076
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (Group B)
Study: 16478755
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg l-dopa
Study: 9771303
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 0.02 mg kg‐1 (Group A, n = 25)
Study: 9771303
Drug: Glycopyrrolate 0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.004 mg kg‐1 (Group G, n = 27)
Study: 7834593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of four sessions in the clinic, four sessions in real-life, and six follow-up sessions in the clinic
Study: 3401658
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ampicillin and 80 mg gentamicin pre‐operatively
Study: 29263079
Drug: Real-time therapeutic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time therapeutic drug monitoring (TDM) with same-day real-time dose adaptation
Study: 26654125
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplement (ONS)
Study: 23047542
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin aspart (Asp)
Study: 23047542
Drug: Postprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postprandial insulin glulisine (Glu)
Study: 16967595
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid and dipyridamole (30‐325 mg daily and 200 mg twice daily)
Study: 16967595
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid only (30‐325 mg daily)
Study: 15518751
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at doses of 0.5, 1, 1.5, and 2 g/day